Lineage Cell Therapeutics, Inc. LCTX.TA Stock
Lineage Cell Therapeutics, Inc. Price Chart
Lineage Cell Therapeutics, Inc. LCTX.TA Financial and Trading Overview
Lineage Cell Therapeutics, Inc. stock price | 497.9 ILA |
Previous Close | 536.4 ILA |
Open | 536.4 ILA |
Bid | 499.3 ILA x N/A |
Ask | 499.8 ILA x N/A |
Day's Range | 505 - 536.2 ILA |
52 Week Range | 3.64 - 536.2 ILA |
Volume | 30.57K ILA |
Avg. Volume | 19.91K ILA |
Market Cap | 902.6M ILA |
Beta (5Y Monthly) | 1.680633 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.45 ILA |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LCTX.TA Valuation Measures
Enterprise Value | 868.2M ILA |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 76.15617 |
Price/Book (mrq) | 1281.1594 |
Enterprise Value/Revenue | 73.254 |
Enterprise Value/EBITDA | -46.889 |
Trading Information
Lineage Cell Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.680633 |
52-Week Change | 11.68% |
S&P500 52-Week Change | 20.43% |
52 Week High | 536.2 ILA |
52 Week Low | 3.64 ILA |
50-Day Moving Average | 5.1 ILA |
200-Day Moving Average | 4.77 ILA |
LCTX.TA Share Statistics
Avg. Volume (3 month) | 19.91K ILA |
Avg. Daily Volume (10-Days) | 12.79K ILA |
Shares Outstanding | 170.17M |
Float | 128.08M |
Short Ratio | N/A |
% Held by Insiders | 4.43% |
% Held by Institutions | 38.36% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -198.76% |
Operating Margin (ttm) | -162.30% |
Gross Margin | 94.33% |
EBITDA Margin | -156.22% |
Management Effectiveness
Return on Assets (ttm) | -9.33% |
Return on Equity (ttm) | -30.68% |
Income Statement
Revenue (ttm) | 11.85M ILA |
Revenue Per Share (ttm) | 0.07 ILA |
Quarterly Revenue Growth (yoy) | -54.40% |
Gross Profit (ttm) | 13.98M ILA |
EBITDA | -18516000 ILA |
Net Income Avi to Common (ttm) | -23558000 ILA |
Diluted EPS (ttm) | -0.57 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 46.81M ILA |
Total Cash Per Share (mrq) | 0.28 ILA |
Total Debt (mrq) | 3.64M ILA |
Total Debt/Equity (mrq) | 5.27 ILA |
Current Ratio (mrq) | 2.883 |
Book Value Per Share (mrq) | 0.414 |
Cash Flow Statement
Operating Cash Flow (ttm) | -32087000 ILA |
Levered Free Cash Flow (ttm) | -16139500 ILA |
Profile of Lineage Cell Therapeutics, Inc.
Country | Israel |
State | CA |
City | Carlsbad |
Address | 2173 Salk Avenue |
ZIP | 92008 |
Phone | 442 287 8990 |
Website | https://lineagecell.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 70 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Q&A For Lineage Cell Therapeutics, Inc. Stock
What is a current LCTX.TA stock price?
Lineage Cell Therapeutics, Inc. LCTX.TA stock price today per share is 497.9 ILA.
How to purchase Lineage Cell Therapeutics, Inc. stock?
You can buy LCTX.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lineage Cell Therapeutics, Inc.?
The stock symbol or ticker of Lineage Cell Therapeutics, Inc. is LCTX.TA.
Which industry does the Lineage Cell Therapeutics, Inc. company belong to?
The Lineage Cell Therapeutics, Inc. industry is Biotechnology.
How many shares does Lineage Cell Therapeutics, Inc. have in circulation?
The max supply of Lineage Cell Therapeutics, Inc. shares is 2M.
What is Lineage Cell Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Lineage Cell Therapeutics, Inc. PE Ratio is now.
What was Lineage Cell Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Lineage Cell Therapeutics, Inc. EPS is -0.45 ILA over the trailing 12 months.
Which sector does the Lineage Cell Therapeutics, Inc. company belong to?
The Lineage Cell Therapeutics, Inc. sector is Healthcare.